Chris Polman

PROF.DR.

19932017
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2017

Natalizumab: The road towards personalized medicine

Vennegoor, A., 2017, 119 p.

Research output: ThesisResearch VU University Amsterdam, graduation VU University AmsterdamAcademic

Open Access

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

Kuhle, J., Hardmeier, M., Disanto, G., Gugleta, K., Ecsedi, M., Lienert, C., Amato, M. P., Baum, K., Buttmann, M., Bayas, A., Brassat, D., Brochet, B., Confavreux, C., Edan, G., Färkkilä, M., Fredrikson, S., Frontoni, M., D'Hooghe, M., Hutchinson, M., De Keyser, J. & 9 othersKieseier, B. C., Kümpfel, T., Rio, J., Polman, C., Roullet, E., Stolz, C., Vass, K., Wandinger, K. P. & Kappos, L., 1 Apr 2016, In : Multiple Sclerosis. 22, 4, p. 533-543 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial

INFORMS study investigator group, Polman, CH. & van Oosten, BW., 12 Mar 2016, In : Lancet. 387, 10023, p. 1075-1084 10 p.

Research output: Contribution to journalArticleAcademicpeer-review